Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants

Pediatric Infectious Disease Journal

Volumn 21, Issue 6, 2002, Pages 518-525

  Faye, Albert ^a   Bertone, Catherine ^a   Teglas, Jean Paul ^b   Chaix, Marie Laure ^c   Douard, Danièle ^d   Firtion, Ghislaine ^e   Thuret, Isabelle ^f   Dollfus, Catherine ^g   Monpoux, Fabrice ^h   Floch, Corinne ⁱ   Nicolas, Joelle ^j   Vilmer, Etienne ^a   Rouzioux, Christine ^k   Mayaux, Marie Jeanne ^b   Blanche, Stéphane ^c  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b INSERM   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HÔPITAL PELLEGRIN   (France)

^e Hôpital Port Royal ^*  (France)

^f TIMONE HOSPITAL   (France)

^g ARMAND TROUSSEAU HOSPITAL   (France)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁱ HÔPITAL LOUIS MOURIER   (France)

^j HÔPITAL ARNAUD DE VILLENEUVE   (France)

^k Hôpital Robert Debré ^*

more..

Author keywords

Infant; Pediatric human immunodeficiency virus; Protease inhibitor; Resistance; Virologic response

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; DIDANOSINE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; IMMUNOLOGY; INFANT; LYMPHOCYTE COUNT; MALE; NEUTROPENIA; NONHUMAN; PERINATAL INFECTION; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS GENE; VIRUS LOAD; VIRUS MUTATION; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; GENETICS; MUTATION; NEWBORN; RISK ASSESSMENT;

DRUG THERAPY, COMBINATION; ENDOPEPTIDASES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMAN; INFANT; INFANT, NEWBORN; MUTATION; RISK ASSESSMENT; RNA, VIRAL; HUMANS;

EID: 0035990354     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200206000-00008     Document Type: Article

References (25)

1. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
2. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection: Italian Register for HIV Infection in Children and the Italian National AIDS Registry
3. Antiretroviral therapy and mortality among children with perinatal HIV infection
4. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children: National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group
5. + lymphocyte count in HIV-infected infants and children
6. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants
7. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: Control of viral replication and absence of persistent HIV-1-specific immune responses
8. 1994 Revised classification system for human immunodeficiency virus infection in children <13 years of age
9. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an international AIDS Society-USA Panel
10. Treatment of human immudeficiency virus 1-infected infants and children with protease inhibitor nelfinavir mesylate
11. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children
12. Growth failure as a prognostic indicator of mortality in pediatric HIV infection
13. Morbidity and mortality in European children vertically infected by HIV-1: The French Pediatric HIV Infection Study Group and European Collaborative Study
14. Predictors of optimal virological response to potent antiretroviral therapy
15. Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy
16. Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy
17. Virological and immunological characteristics of HIV treatment failure
18. Viral dynamics of HIV: Implications for drug development and therapeutic strategies
19. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1
20. Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants vertically infected with human immunodeficiency virus type 1
21. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants
22. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy